3SBio Stock

3SBio EBIT Margin

The EBIT Margin (Operating Margin) of 3SBio (1530.HK) as of Aug 13, 2026 is 59.59 %. In the previous year, EBIT Margin (Operating Margin) was 28.67 % — a change of 107.82% (higher).

EBIT Margin

59.59 %

YoY

107.82%

Last updated:

EBIT Margin (Operating Margin) of 3SBio is 2026 59.59 % . EBIT Margin (Operating Margin) of 3SBio was 2025 28.67 % . It decreases by 107.82% higher compared to the previous year.

3SBio's operating (EBIT) margin stands at 59.6%, up from 28.6% several years earlier.

Access this data via the Eulerpool API
Get Free API Key

3SBio Stock analysis

What does 3SBio do? 3SBio Inc. is a biopharmaceutical company from China that specializes in the research, development, manufacturing, and marketing of biological products. It was founded in 1993 in Shenyang, a city in northeast China, and its headquarters are now in Beijing. 3SBio's business model is based on the development and manufacturing of biopharmaceuticals that are used to treat cancer, autoimmune diseases, and other serious illnesses. The company focuses on biological medicines such as proteins, antibodies, and peptides that are produced using genetic technology. 3SBio operates a wide range of business sectors, including the manufacturing and sale of biopharmaceutical products, the manufacturing and sale of generics and biosimilar products, and research and development in the biotechnology field. The company also has several subsidiaries and joint ventures, including 3SBio International Holding, Sunshine Guojian Pharmaceutical, and Target Pharma. A well-known product of 3SBio is erythropoietin (EPO), which is used in the treatment of anemia. The company also has a portfolio of other biopharmaceutical products that are used to treat cancer, autoimmune diseases, and other serious illnesses. The history of 3SBio goes back to 1993 when it was founded as Shenyang Sunshine Pharmaceutical. In 2001, the company was renamed "Shenyang Sunshine Pharmaceutical Co. Ltd. 3S Bio" and focused on biological therapy. In 2007, the company successfully listed on the Hong Kong Stock Exchange and received the name 3SBio. In 2013, the company was privatized and acquired by a consortium of Chinese investment companies. 3SBio has a strong presence in China and is also expanding into international markets. The company has distribution partnerships in Asia, Europe, and North America, and plans to enter more markets. Overall, 3SBio is a leading company in China in the field of biopharmaceuticals that focuses on the treatment of serious illnesses. The company aims to be a leader in research and development, as well as in the manufacturing and sale of innovative products, and to expand its presence in global markets. 3SBio is one of the most popular companies on Eulerpool.

Frequently Asked Questions about 3SBio stock

EBIT Margin (Operating Margin) of 3SBio is 59.59 % in 2026.

EBIT Margin (Operating Margin) of 3SBio changed from 28.67 % to 59.59 %, representing a 107.82% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBIT Margin (Operating Margin) 3SBio since 2006 – with annual values, charts, and detailed analysis.

EBIT Margin measures operating profitability as a percentage of revenue. It shows how much profit a company makes from operations before interest and taxes.

A 'good' varies by industry and company stage. On Eulerpool, you can compare EBIT Margin (Operating Margin)'s 3SBio with sector peers and the industry average to assess whether it is attractive.

To evaluate EBIT Margin (Operating Margin)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EBIT Margin (Operating Margin).

Access this data via the Eulerpool API
Get Free API Key

Margins — 3SBio

Gross MarginEBIT MarginEBITDA MarginNet MarginFCF MarginR&D / RevenueTax RatePayout RatioPre-Tax MarginOCF MarginSGA/RevenueOpEx/RevenueReinvestment Rate

All Key Metrics — 3SBio